Tissue Engineering Market Report 2025

The tissue engineering market size has grown rapidly in recent years. It will grow from $15.21 billion in 2024 to $17.48 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to advancements in biomaterials, growing aging population, increasing incidence of chronic diseases, regulatory support for regenerative medicine, rising patient demand for organ transplants.

The tissue engineering market size is expected to see rapid growth in the next few years. It will grow to $29.92 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to precision medicine approaches, increasing focus on immunomodulation, expanding applications in orthopedics, increased funding and investment, rising prevalence of chronic diseases. Major trends in the forecast period include integration of nanotechnology, 3d cell culture techniques, development of organ-on-a-chip technology, artificial intelligence integration, innovative cell sources.

The rising prevalence of chronic diseases and trauma emergencies is anticipated to drive the growth of the tissue engineering market in the future. Chronic diseases are defined as clinical conditions lasting three months or longer that can typically be managed but not cured, while trauma emergencies refer to physical injuries requiring immediate medical attention due to their sudden onset and severity, such as traumatic brain injuries. Healthcare professionals widely adopt tissue engineering for its numerous benefits in treating chronic disorders and trauma, helping to prevent end-stage treatment failures, including autologous or allograft transplantation, xenotransplantation, and artificial substitutes. For example, a 2023 report by the World Health Organization (WHO), a U.S.-based agency focused on promoting global health and coordinating responses to health emergencies, noted that approximately 2.4 billion people worldwide live with chronic diseases, with significant increases in conditions like diabetes and cardiovascular diseases. This growing prevalence underscores the urgent need for advanced medical treatments, including tissue engineering solutions. Furthermore, the Centers for Disease Control and Prevention (CDC) reported in 2023 that traumatic brain injuries (TBIs) remain a critical issue in the United States, with around 223,000 hospitalizations and 60,000 deaths annually, highlighting the necessity for effective interventions. Consequently, the increasing incidence of chronic illnesses and trauma emergencies is expected to significantly drive growth in the tissue engineering market.

The rising prevalence of cardiovascular disorders is projected to propel the growth of the tissue engineering market in the future. Cardiovascular disorders, or cardiovascular diseases (CVD), represent a class of medical conditions affecting the heart and blood vessels. Tissue engineering provides promising solutions for repairing and regenerating damaged cardiac and vascular tissues. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with about 4 million males and 3.6 million females living with these conditions. These diseases account for roughly 27% of all deaths in the UK, translating to over 170,000 fatalities annually, or about 480 deaths each day, equating to one death every three minutes. Therefore, the increasing prevalence of cardiovascular disorders is driving the growth of the tissue engineering market.

Technological advancements are a key trend gaining traction in the tissue engineering market. Major companies in this sector are concentrating on research and development to innovate products that offer improved solutions and reinforce their market positions. For instance, in August 2024, CytoNest Inc., a U.S.-based company specializing in scalable 3D cell culture platforms for adherent cell manufacturing, launched its first commercial product: a fiber scaffold designed to optimize cell manufacturing and tissue engineering. This product, known as the CytoSurge 3D fiber scaffold, has applications in cell research, biopharmaceuticals, cell therapeutics, and the development of cultured meat and seafood.

Key companies are strategically forming partnerships and collaborations with start-ups and mid-sized firms in the tissue engineering market to enhance their product and service offerings. These strategic alliances enable companies to expand their existing product portfolios and geographical presence. For example, in June 2023, Regen Lab, a Swiss-based commercial-stage medical technology company focused on the research, development, registration, manufacturing, and commercialization of proprietary tissue engineering products, entered into a collaboration agreement with Long Island University (LIU) and the Dassault Systèmes Group (3DS). According to the terms of this agreement, LIU and RegenLab USA will pool resources to establish an industrial innovation accelerator, a new center of excellence dedicated to regenerative medicine and tissue engineering. Long Island University is a U.S.-based educational institution, while Dassault Systèmes Group is a France-based software corporation.

In October 2022, Geistlich Pharma, a US-based company specializing in bone, cartilage, and tissue regeneration, completed the acquisition of Lynch Biologics, LLC. The financial specifics of this acquisition were not disclosed. This strategic move serves to bolster Geistlich's existing regenerative product portfolio and augments its growth prospects within the field. Lynch Biologics, the acquired company, is also based in the US and is known for its focus on regenerative medicine and tissue engineering. They specialize in supplying advanced biotechnology products aimed at fostering healing and tissue regeneration.

Major companies operating in the tissue engineering market include Medtronic plc, Zimmer Biomet, Organogenesis Holdings Inc., Integra LifeSciences, Stryker Corporation, DePuy Synthes Companies, B. Braun Melsungen AG, RTI Surgical Inc., AbbVie Inc., Becton Dickinson and Company, Baxter International Inc., BioTime Inc., Vericel Corporation, Smith and Nephew, Athersys Inc., Tissue Regenix Group plc, Xeltis AG, Prellis Biologics, Bit Bio, Be Biopharma Inc., TELA Bio Inc., Orthocell Limited.

North America was the largest region in the tissue engineering market in 2024. Asia-Pacific is expected to be the fastest-growing region in the tissue engineering market during the forecast period. The regions covered in the tissue engineering market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tissue engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tissue engineering is a specialized field within biomedical engineering that combines biological and engineering methodologies. It aims to generate three-dimensional tissue and cellular products both in vivo (within a living organism) and in vitro (outside a living organism) by modifying cell growth conditions and utilizing appropriate cell isolates from donor tissues alongside biocompatible scaffold materials. The primary objective is to restore, repair, maintain, or enhance tissue function by replacing or regenerating damaged tissues, thereby improving human body functions.

Key categories within tissue engineering encompass synthetic scaffold materials, biologically derived scaffold materials, and other methodologies. Synthetic scaffold materials are synthetic polymers composed of fibrous proteins that simulate an extracellular matrix, promoting favorable cellular responses and behaviors in tissue engineering applications. These materials find diverse applications across orthopedics and musculoskeletal treatments, neurology, cardiovascular procedures, skin and integumentary therapies, dental applications, among others. Various end-users including hospitals, clinics, and ambulatory facilities utilize these materials for their respective medical applications.

The tissue engineering market research report is one of a series of new reports that provides tissue engineering market statistics, including the tissue engineering industry global market size, regional shares, competitors with a tissue engineering market share, detailed tissue engineering market segments, market trends and opportunities, and any further data you may need to thrive in the tissue engineering industry. This tissue engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tissue engineering market consists of sales of reparative cells, bioreactive molecules, such as cytokines, growth factors, biomaterials, and bioreactors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.